Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, August 26 '25)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. NAQVI ZA
    Residual Scars That Grow: The Hidden Threat of Delayed Pulmonary Fibrosis Post-COVID-19.
    Am J Respir Crit Care Med. 2025 Aug 22. doi: 10.1164/rccm.202506-1558.
    PubMed        

  2. BALDWIN MR, Garcia CK
    Reply to Naqvi: Residual Scars That Grow: The Hidden Threat of Delayed Pulmonary Fibrosis Post-COVID-19.
    Am J Respir Crit Care Med. 2025 Aug 22. doi: 10.1164/rccm.202507-1624.
    PubMed        


    Antiviral Res

  3. TERATAKE Y, Okamura T, Ishizaka Y
    SMAD5 phosphorylation by ALK1 is modulated by the interaction of the spike protein of SARS-CoV-2 and angiotensin-converting enzyme 2.
    Antiviral Res. 2025;242:106261.
    PubMed         Abstract available

  4. GOLDIN K, Brackney B, Lutterman T, Williamson BN, et al
    Dexamethasone treatment does not alter mortality but reduces pulmonary pathology in Nipah virus-infected Syrian hamsters.
    Antiviral Res. 2025;242:106263.
    PubMed         Abstract available

  5. LEI F, Shu J, Xia C, Lei Y, et al
    Viral determinants of cis- and trans-cleavage by SARS-CoV-2 Nsp3 and an on-off reporter for monitoring intracellular protease activity.
    Antiviral Res. 2025;242:106262.
    PubMed         Abstract available


    BMJ

  6. TSERGAS N
    Why scientists are rethinking the immune effects of SARS-CoV-2.
    BMJ. 2025;390:r1733.
    PubMed        


    Clin Infect Dis

  7. VEGA OCASIO D, Patel NN, Leidman E, Marcenac P, et al
    Evaluation of Coronavirus Disease 2019 and Influenza-like Illness Surveillance Case Definitions in a Prospective Cohort of Healthcare Personnel in Peru.
    Clin Infect Dis. 2025 Aug 19:ciaf340. doi: 10.1093.
    PubMed         Abstract available

  8. NADIG N, Bhimraj A, Cawcutt K, Chiotos K, et al
    2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.
    Clin Infect Dis. 2025 Aug 20:ciaf355. doi: 10.1093.
    PubMed         Abstract available

  9. REZAHOSSEINI O, Staehr Jensen JU, Rahimi HK, Jensen NE, et al
    Immunogenicity and Safety of the COVID-19 mRNA Vaccine Coadministered with Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.
    Clin Infect Dis. 2025 Aug 18:ciaf455. doi: 10.1093.
    PubMed         Abstract available


    Eur J Radiol

  10. YANAGAKI S, Murayama A, Kondo K, Sato T, et al
    Payments from intravascular embolisation device companies to medical professionals and institutions in Japan (2019-2023): An open payment data analysis.
    Eur J Radiol. 2025;191:112362.
    PubMed         Abstract available


    Graefes Arch Clin Exp Ophthalmol

  11. MARTINEZ-ALBERT N, Nieto-Fernandez JC, Garcia-Marques JV
    Keratometry repeatability in healthy and post-refractive surgery eyes: a comparison of two swept-source devices.
    Graefes Arch Clin Exp Ophthalmol. 2025 Aug 16. doi: 10.1007/s00417-025-06893.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  12. STERN RA, Bashaw K, Shackelford CE, Talbot TR, et al
    The unintended burden of transmission-based precautions for suspected COVID-19 in the ambulatory setting.
    Infect Control Hosp Epidemiol. 2025 Aug 19:1-3. doi: 10.1017/ice.2025.10229.
    PubMed         Abstract available


    Int J Infect Dis

  13. TENG O, Quek AML, Ooi DSQ, Wang S, et al
    High CD4(+) T-cell Responses in Seronegative Individuals Following SARS-CoV-2 Exposure during a Dormitory Outbreak.
    Int J Infect Dis. 2025 Aug 20:108024. doi: 10.1016/j.ijid.2025.108024.
    PubMed         Abstract available


    J Infect

  14. LIU B, Song S, Liu W, Hu Y, et al
    Post-COVID-19 multimorbidity incidence by prior vaccination status in people with a pre-existing comorbidity: A population-based cohort study.
    J Infect. 2025;91:106597.
    PubMed         Abstract available

  15. AHIMBISIBWE G, Greenwood D, Wilkinson KA, Gahir J, et al
    Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses.
    J Infect. 2025 Aug 21:106598. doi: 10.1016/j.jinf.2025.106598.
    PubMed         Abstract available

  16. DIETL B, Henares D, Cuchi E, Blanco-Fuertes M, et al
    Differential nasopharyngeal microbiota patterns: A Comparative Study of Pneumococcal Pneumonia, COVID-19, and Healthy Adults.
    J Infect. 2025 Aug 14:106589. doi: 10.1016/j.jinf.2025.106589.
    PubMed         Abstract available

  17. MCGEOCH LJ, Foulkes S, Whitaker H, Munro K, et al
    Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: The SIREN cohort study.
    J Infect. 2025;91:106585.
    PubMed         Abstract available


    J Med Virol

  18. URBANSKI AH, Freitas FCP, Gomes TMFDF, Schemberger MO, et al
    Genetic Variants Affect Distinct Metabolic Pathways in Pediatric Multisystem Inflammatory Syndrome and Severe COVID-19.
    J Med Virol. 2025;97:e70556.
    PubMed         Abstract available

  19. ZHOU M, Yang J, Tian B, Wang X, et al
    Spatial Proteomics Using BiFCPL Identifies Regulators of DMV Formation Involved in Coronavirus Replication.
    J Med Virol. 2025;97:e70547.
    PubMed         Abstract available


    J Virol

  20. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    PubMed         Abstract available

  21. EL ZOWALATY ME, Taylor LJ, Son Y, Lee H, et al
    Discovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons (Columba livia domestica).
    J Virol. 2025 Aug 20:e0111225. doi: 10.1128/jvi.01112.
    PubMed         Abstract available

  22. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed         Abstract available

  23. CHI X, Liang X, Vaddadi K, Zhang X, et al
    SARS-CoV-2 Nsp15 endoribonuclease subverts host defenses to enhance viral fitness in lung cells.
    J Virol. 2025 Aug 21:e0117525. doi: 10.1128/jvi.01175.
    PubMed         Abstract available

  24. HE Q, Zou Y, Yu B, Yuan Q, et al
    A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.
    J Virol. 2025 Aug 21:e0067425. doi: 10.1128/jvi.00674.
    PubMed         Abstract available


    JAMA

  25. TURNER NA, Hamasaki T, Doernberg SB, Lodise TP, et al
    Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
    JAMA. 2025 Aug 13. doi: 10.1001/jama.2025.12543.
    PubMed         Abstract available

  26. ANDERER S
    COVID-19 Vaccines Averted 2.5 Million Deaths, Mostly Among Older Adults.
    JAMA. 2025 Aug 15. doi: 10.1001/jama.2025.11001.
    PubMed        


    Lancet Infect Dis

  27. JOHNSON A
    Racism in the COVID-19 pandemic.
    Lancet Infect Dis. 2025;25:964.
    PubMed        


    Nature


  28. Cancelling mRNA studies is the highest irresponsibility.
    Nature. 2025;644:579.
    PubMed        

  29. COSTELLO A
    David Nabarro obituary: global-health leader who fought malnutrition, malaria, Ebola and COVID-19.
    Nature. 2025;644:870.
    PubMed        
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »